Czech Society for Rheumatology guidelines for biological treatment with TNF blocking agents - Supplement of standard treatment protocol in rheumatoid arthritis;Deporučení České revmatologické společnosti k biologické léčbě blokádou TNF - Doplněk standardních léčebných postupů u revmatoidní artritidy

Ceska Revmatologie

Volumn 12, Issue 1, 2004, Pages 20-29

  Vencovsky J ^b   Tegzova D ^b   Krofta, K ^a   Pavelka, K ^b  

^a FAKULTNÍ THOMAYEROVA NEMOCNICE   (Czech Republic)

^b INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

Author keywords

Rheumatoid arthritis (RA); Standard protocol; TNF blocking agents; Tubercolosis

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE; SOMATOSTATIN; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR;

ARTICLE; BIOLOGICAL THERAPY; CLINICAL PROTOCOL; CZECH REPUBLIC; DATA ANALYSIS; DRUG INDICATION; DRUG USE; HUMAN; INFECTION RISK; MEDICAL SOCIETY; PRACTICE GUIDELINE; REGISTER; RELIABILITY; RHEUMATOID ARTHRITIS; SOCIOECONOMICS; TUBERCULOSIS;

EID: 1542329184     PISSN: 12107905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Pavelka K, Bečvář R, Olejárová M, Sainerová A. Standardní postupy v revmatologii. Revmatoidní artritida. Čes Revmatol 1999; 7(Suppl 1): 4-8.
2. Vencovský J, Tegzová D, Pavelka K. Doplněk standardních postupů u revmatoidní artritidy. Čes Revmatol 2002; 10: 31-40.
3. Smolen JS, Breedveld FC, Burmester GR, et al. Consensus statement on the initiation and continuation of tumor necrosis factor blocking therapies in rheumatoid artritis. Ann Rheum Dis 2000; 59: 504-5.
4. Furst DE, Keystone EC, Breedveld FC, et al. Updated consensus statement on tumor necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001). Ann Rheum Dis 2001; 60(Suppl 3): iii2-5.
5. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis 2002; 61(Suppl 2): ii2-7.
6. Wolfe F, Cush JJ, O'Dell JR, et al. Consensus recommendations for the assessment and treatment of rheumatoid arthritis. J Rheumatol 2001; 28: 1423-30.
7. American college of rheumatology subcommittee on rheumatoid arthritis guidelines. Guidelines for the management of rheumatoid arthritis. 2002 update. Arthritis Rheum 2002; 46: 328-46.
8. Bathon JM, Martin RW, Fleischman RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. New Engl J Med 2000; 22: 1586-93.
9. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med 1999; 130: 478-86.
10. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9.
11. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.
12. Maini R, StClair EW, Breedveld F, et al. Infliximab (chimeric anti-tumor necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 1932-9.
13. Lipsky PE, van der Heijde DMFM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. New Engl J Med 2000; 22: 1594-602.
14. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. New Engl J Med 2000; 11: 763-9.
15. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 1443-50.
16. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
17. Rau R. Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis 2002; 61 (Suppl 2): ii70-3.
18. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
19. St. Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis. Arthritis Rheum 2002; 46: 1451-9.
20. Braun J, Sieper J, van der Heijde D. Definition of discontinuation of anti-tumor necrosis factor therapy in rheumatoid arthritis: a preliminary proposal. Ann Rheum Dis 2003; 62: 1023-4.
21. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998; 317: 180-81.
22. Hotline American College of Rheumatology, březen 2003, http://www.rheumatology.org/research/hotline/index.asp a http://www.fda.gov/ohrms/dockets/ac/acmenu.htm
23. Hamilton CD. Tuberculosis in the cytokine era: What rheumatologists need to know. Arthritis Rheum 2003; 48: 2085-91.
24. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. Arthritis Rheum 2003; 48: 2122-7.
25. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 148-55.
26. Salmon D on behalf of GTI and AFSSAPS. Recommendations about the prevention and management of tuberculosis in patients taking infliximab. Joint Bone Spine 2002; 69: 170-2.
27. Mariette X, Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 2003; 62: 791.